[Federal Register: February 11, 2009 (Volume 74, Number 27)]
[Notices]
[Page 6921]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr11fe09-84]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 6, 2009, Siegfried
(USA), Inc., 33 Industrial Park Road, Pennsville, New Jersey 08070,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the basic classes of
controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Glutethimide (2550)........................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Oripavine (9330)...........................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
    Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 13, 2009.

    Dated: February 5, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
 [FR Doc. E9-2910 Filed 2-10-09; 8:45 am]

BILLING CODE 4410-09-P